Seth Klarman Declares Ownership of Fledgling Biotech

Seth Klarman Declares Ownership of Fledgling Biotech


Translate Bio is developing a drug to treat cystic fibrosis. The drug received orphan designation in 2015 and is undergoing clinical trial Seth Klarman has declared 14.5% interest in a Massachusetts-based startup that is working on a new drug to treat cystic fibrosis, which affects more than 70,000 people in the world.



from Biotech News